These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2802908)

  • 1. [Induction of LAK cells and CTL in patients with brain tumor and research of its clinical application].
    Moriki A
    Nihon Geka Hokan; 1989 Jan; 58(1):107-18. PubMed ID: 2802908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
    Yoshida S; Takai N; Ono K; Saito T; Tanaka R
    No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The anti-tumor efficacy of lymphokine-activated killer (LAK) cells induced in vitro from peripheral blood lymphocytes of patients with malignant glioma].
    Shimizu K; Miyao Y; Okamoto Y; Matsui Y; Ushio Y; Tsuda N; Hayakawa T; Ishida N; Mogami H
    No To Shinkei; 1986 Mar; 38(3):265-71. PubMed ID: 3085695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody].
    Kikuchi T; Sakai H; Nakamura N; Watanabe M; Ohno T
    No To Shinkei; 1990 Jun; 42(6):575-80. PubMed ID: 2119634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.
    Morikawa Y; Watanabe S; Kodama T
    Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.
    Jacobs SK; Wilson DJ; Kornblith PL; Grimm EA
    Cancer Res; 1986 Apr; 46(4 Pt 2):2101-4. PubMed ID: 3512079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
    Taguchi T; Domoto K
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
    Ikawa T; Eura M; Fukiage T; Murakami H; Yamasaki S; Fukuda K; Fukushima M; Arishima S; Maehara T; Ishikawa T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
    Itoh K; Tilden AB; Balch CM
    Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical studies of adoptive immunotherapy of human disseminated brain tumors with LAK cells and recombinant interleukin-2].
    Okamoto Y; Shimizu K; Miyao Y; Yamada M; Ushio Y; Matsui Y; Hayakawa T; Tago H; Ikeda H
    No To Shinkei; 1986 Jun; 38(6):593-8. PubMed ID: 3488068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
    Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
    Yoshida S; Tanaka R; Takai N; Ono K
    Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
    Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Basic and clinical study of adoptive immunotherapy using cytotoxic T lymphocyte (CTL) against cancers].
    Kitsukawa K
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1448-54. PubMed ID: 2543306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies on adoptive immunotherapy using recombinant interleukin 2].
    Sugiyama Y; Takao H; Saji S; Sakata K
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1307-13. PubMed ID: 3488028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.